Treatment and Diagnosis of Chronic Lymphocytic Leukemia (CLL), Breast Cancer, and Other Cancers through Use of a Monoclonal Antibody

Published date: Feb. 1, 2012

Technology description

Summary

Today there are a variety of treatment options for cancer, but many are non-specific, which results in normal cells being destroyed along with the malignant ones. Anemia, fatigue, immunodeficiency, and vomiting are just a few side effects of chemotherapy. Current monoclonal antibody lymphoma treatments most B cells in the patient, thus crippling the immune system. Rare infections and skin cancers can result. Moreover, a specific marker for Chronic Lymphocytic Leukemia (CLL) does not exist on the market today. Patients "wait and see" if the symptoms progress in the early stages of the disease before a diagnosis is made. Instead of being treated immediately, the disease could lurk for years. Detection of residual disease after therapy is problematic as well.

Description

This novel technology is a way to diagnose and treat CLL, breast cancer, and other cancers.

Institution

University of California, San Diego

联系我们

叶先生

电 话：021-65679356

手 机：13414935137

邮 箱：yeyingsheng@zf-ym.com